Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2020

View Archived Issues

Zebrafish embryos xenografted with ACC cells to study antitumor effects of abiraterone acetate

Noncoding RNA protects blood vessel walls

Glutaminase 1 is NASH target

Sojournix begins phase II study of SJX-653 for vasomotor symptoms due to menopause

FDA approves Fluad Quadrivalent influenza vaccine for use in adults age 65 years and older

Phase II results for olaparib with or without cediranib in mCRPC

Novel homeostatic lipid mediators show neuroprotection in rat model of cerebral ischemia

ASOs targeting GYS1 show promise in mouse model of Pompe disease

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents boric acid derivatives

Blue Sky Pharmaceuticals describes new mu-opioid receptor agonists for pain

GlaxoSmithKline and ViiV Healthcare present compounds for HIV infection

Guangzhou Henovcom Bioscience identifies new NR1H4 agonists

siRNA reduction of HBV antigens increases vaccine efficacy in persistent mice HBV infections

New USP28 and USP25 inhibitors presented by FORMA Therapeutics

Herantis reports topline data from phase I/II study of CDNF in Parkinson's disease

Bluebird bio presents phase I/II data on LentiGlobin for sickle cell disease

COVID-19 spreading but not yet pandemic disease, says WHO

Moderna releases novel coronavirus vaccine mRNA-1273 to NIAID for phase I trial

Phase II study of IO-102 in NSCLC cleared to continue following futility analysis

Ascentage cleared to begin phase Ib/II trial in China with APG-1387 for pancreatic cancer

Affimed studies AFM-24 in phase I/II study for advanced solid tumors